Report contents
Business model
Business model: a cystic fibrosis engine funding four launches
Vertex sells oral pills and a one-time cell therapy for a short list of genetically defined diseases. The customer is rarely the patient: U.S. commercial insurers and pharmacy benefit managers, Medicaid and Medicare, and government health systems abroad decide what gets reimbursed, and patients pay modest cost sharing. Vertex reported $3.44 billion of third-quarter 2026 revenue, $2.17 billion in the U.S. and $1.27 billion elsewhere, and raised full-year guidance to $13.15–13.25 billion. This is a research-based specialty pharmaceutical company, commercially mature in cystic fibrosis and in an expansion stage everywhere else. The stretch, not the CF base, is what the next three years test.
One franchise still sets the price
Almost all of the money comes from cystic fibrosis. Of the guided $13.15–13.25 billion for 2026, management expects $500 million or more from CASGEVY and JOURNAVX combined and $40–50 million from PALSONIFY, the rare-endocrine drug acquired with Crinetics.
| FY2026 guidance | USD bn | | Total revenue | 13.15–13.25 | | CASGEVY + JOURNAVX | ≥0.50 | | PALSONIFY (from September 1) | 0.04–0.05 | | Implied cystic fibrosis and other | ~12.6–12.7 |
The last line is a residual calculated from the company's ranges.
Growth of 12% in the quarter came from what Vertex described as strong CF patient demand including new ALYFTREK initiations, higher realized U.S. CF net prices, and first contributions from the newer products; outside the U.S., revenue rose 16% with a foreign-exchange tailwind that adds about 150 basis points to full-year growth. The arithmetic is the point. The eligible CF population is finite and already largely treated, so each extra point of revenue leans more on price and on moving patients to the once-daily regimen than on finding new patients. Payer terms, not clinical data, are the swing variable for the earnings base.
Competition inside CF is thin enough that Vertex prices against payer budgets rather than against a rival's list price. That is also why the switching campaign matters beyond this year: a newer molecule carries its own exclusivity clock, so moving patients to ALYFTREK extends the franchise's protected life, at the cost of managing two cohorts and their adherence at the same time.
Payers negotiate; patients do not
Pricing power sits on the other side of the table. Vertex negotiates U.S. CF reimbursement with a handful of PBMs, and one formulary tier change or tighter prior authorization can move realized net price more than a mid-stage trial result. Outside the U.S., national systems set prices administratively, which caps per-patient revenue on the 37% international leg even where volume grows. CASGEVY is a different business inside the same company: a one-time infusion given at authorized treatment centers, recognized when a patient completes the multi-week sequence of cell collection, editing, and reinfusion. Revenue there is lumpier, depends on center throughput and on a single payer authorization for a very expensive procedure, and does not recur.
The bill for four new franchises
The expansion is already expensive. Crinetics closed on September 1 for about $9.0 billion of net cash, partly funded with a $4.5 billion term loan, and cash and securities fell from $12.3 billion at December 31 to $9.8 billion. Povetacicept, filed in immunoglobulin A nephropathy (IgAN, a rare kidney disease), has a PDUFA date of November 30 and would become a fifth pillar. Combined GAAP R&D, acquired IPR&D, and SG&A reached $2.2 billion in the quarter against $1.5 billion a year earlier, including roughly $500 million of Crinetics compensation and transaction expense, and full-year guidance rose to $7.15–7.2 billion. Non-GAAP net income was $1.2 billion in both quarters: revenue grew 12% and adjusted earnings did not grow at all. Launch spending is committed before the new franchises have shown they can carry it, which is the real tradeoff in the model today, not the pipeline's scientific risk.
What would change the judgment
If U.S. CF net price keeps rising while prescription volume is flat, Vertex is a price-led franchise carrying payer-concentration risk, and the diversification spending looks late and expensive. If ALYFTREK switching plus povetacicept, PALSONIFY, and JOURNAVX instead push non-CF revenue well past the $500 million-plus line in 2027 while CF price holds, the concentration argument weakens and the higher cost base reads as investment. A rival CFTR modulator advancing into late-stage trials would call into question the durability of the cash engine itself; so far no competitor has brought one to market, and Vertex's own next-generation CF program is the hedge it controls. Vertex does not disclose CF unit volumes, so U.S. CF revenue growth alongside flat third-party prescription trends is the earliest evidence of a price-only franchise.
Questions worth following
- Can Vertex grow cystic fibrosis volume as the treated pool matures?
CF supplies more than 95% of guided 2026 revenue, so whether growth comes from new patients or from price decides how exposed the model is to a few payer contracts. Volume growth would support durability of the earnings base; price-only growth raises the stakes on reimbursement terms.
- Can Vertex's non-cystic-fibrosis products carry the double-digit cash-flow growth its price implies?
The supplied DCF and the market price both lean on growth the cystic fibrosis franchise alone may not sustain. If new products do not scale, the 12%-to-3% fade is too generous, and the gap between price and modeled value closes from the wrong direction.
- Will a rival CFTR modulator reach the U.S. market before 2029?
The franchise that funds every other program has no approved competitor, which is what lets Vertex price against payer budgets. A credible entrant would compress price and share in the one market that produces nearly all earnings, while a thin competitive field keeps the cash engine intact for the expansion.
Financial quality
Financial quality: cash still backs the earnings; funding is new
Vertex's profits do turn into cash. Across the four profitable years from FY2021 to FY2025, operating cash flow ran between 0.92x and 1.24x net income, and free cash flow was positive in four of the five. The loss year, FY2024, came from roughly $4.9 billion of operating expense, mostly the Alpine Immune Sciences acquired IPR&D charge; it was an accounting event, not a broken franchise. Gross margin has held above 85%, and capital expenditures have not exceeded 3.6% of revenue.
| USD bn unless noted | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Q2 2026 (3 mo.) | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue | 7.57 | 8.93 | 9.87 | 11.02 | 12.07 | 3.33 | Strong (12.4% CAGR) |
| Gross margin % | 88.1 | 87.9 | 87.2 | 86.1 | 85.1 | 85.3 | Exceptional |
| Operating income | 2.78 | 4.31 | 3.83 | (0.23) | 4.76 | 1.25 | Strong |
| Net margin % | 30.9 | 37.2 | 36.7 | (4.9) | 32.7 | 33.0 | Exceptional |
| ROE % | 24.9 | 27.7 | 23.0 | (3.2) | 21.2 | 5.4 (quarter) | Exceptional |
| ROA % | 18.6 | 21.0 | 17.7 | (2.4) | 15.1 | 4.0 (quarter) | Strong |
| Liabilities / assets % | 24.8 | 23.3 | 22.7 | 27.2 | 28.6 | 26.1 | Strong |
| Current ratio | 4.46 | 4.83 | 3.99 | 2.69 | n.d. | n.d. | Strong |
| Operating cash flow | 2.64 | 4.13 | 3.54 | (0.49) | 3.63 | 1.12 | Strong |
| Free cash flow | 2.41 | 3.92 | 3.28 | (0.79) | 3.19 | 1.01 | Strong |
| Operating cash flow / net income (x) | 1.13 | 1.24 | 0.98 | n.m. | 0.92 | 1.02 | Strong |
| Capex / revenue % | 3.0 | 2.4 | 2.6 | 2.7 | 3.6 | 3.3 | Adequate |
The Q2 2026 column covers three months and is not comparable with the annual figures; current assets are not broken out at the later dates, so the current ratio cannot be extended.
What changed in 2026 is financing. Vertex said in its November 2 results release that cash and marketable securities fell to $9.8 billion at September 30 from $12.3 billion at December 31, 2025, after about $9.0 billion of net cash went to the Crinetics Pharmaceuticals acquisition and share repurchases, partly offset by a $4.5 billion term loan. FY2025's $2.26 billion financing outflow was comfortably covered by $3.19 billion of free cash flow. The Crinetics purchase was not, and this is the first time in the period that Vertex has taken on material debt while buying back stock.
| USD bn, single quarter | Revenue | Gross margin % | Net income | Net margin % | Total assets | Total liabilities | Operating cash flow | Free cash flow | Assessment | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 Q1 | 2.77 | 87.0 | 0.65 | 23.5 | 22.88 | 6.38 | 0.82 | 0.78 | Adequate | Margin dip |
| FY2025 Q2 | 2.96 | 86.5 | 1.03 | 34.8 | 24.04 | 6.86 | 1.07 | 0.93 | Strong | Recovering |
| FY2025 Q3 | 3.08 | 86.4 | 1.08 | 35.1 | 24.86 | 7.54 | 1.24 | 1.14 | Strong | Steady |
| FY2025 Q4 | 3.23 | 85.4 | 1.19 | 36.8 | 26.14 | 7.48 | 0.50 | 0.35 | Strong | Cash conversion eased |
| FY2026 Q1 | 2.99 | 86.6 | 1.03 | 34.4 | 26.48 | 7.12 | 1.43 | 1.29 | Strong | Cash rebound |
| FY2026 Q2 | 3.33 | 85.3 | 1.10 | 33.0 | 27.42 | 7.17 | 1.12 | 1.01 | Strong | Margin easing |
Six quarters are available; earlier periods are not shown. Net PP&E is not disclosed at these dates, so fixed assets are omitted.
Returns rest on margins, not leverage
FY2025 ROE of 21.2% comes from a 32.7% net margin and an equity multiplier of 1.40, so it is earned. ROA fell from 21.0% in FY2022 to 15.1% in FY2025 while revenue rose 35%, because cash, securities and then acquisition balances grew faster than sales. Asset turnover of 0.46 understates the commercial business: net PP&E was $1.46 billion at the end of 2022, and most of the $26.14 billion of assets at December 31, 2025 was cash and investments. That cuts two ways. The return on the assets that actually make and sell drugs is very high, and any figure measured on total assets or a larger post-deal equity base will look weaker even if the cystic fibrosis business is unchanged.
Deal accounting resets GAAP earnings, not cash
Gross margin slipped 2.8 points, from 88.1% in FY2021 to 85.3% in the June 2026 quarter, which product mix explains well enough as CASGEVY and ALYFTREK carry different cost profiles from the legacy portfolio. The larger move sits below the gross line. Vertex raised 2026 GAAP combined R&D, acquired IPR&D and SG&A guidance to $7.15 billion–$7.2 billion, including about $500 million of Crinetics compensation and transaction expense, against revenue guidance of $13.15 billion–$13.25 billion. GAAP net income was $654 million in the September quarter against $1.1 billion a year earlier.
Most of that is deal accounting, and the treatment is conservative. Acquired IPR&D is expensed instead of capitalized, so goodwill has barely moved from $1.09 billion since FY2022 and deal-quarter earnings absorb the hit that would otherwise sit on the balance sheet. The FY2024 tax provision of $0.78 billion against a pre-tax loss shows how much of such a charge is non-deductible. Earnings quality is fine; year-to-year comparability is not.
Working capital, the term loan and what to check
Inventory is the working-capital question. It rose from $0.46 billion at the end of 2022 to $1.50 billion at June 30, 2025, and annual turns fell from 2.85 to 1.57 between FY2021 and FY2024. Mid-2025 inventory equaled roughly 3.7 quarters of cost of goods sold, against 1.7 quarters in FY2022. Launch stock for ALYFTREK, CASGEVY and JOURNAVX explains part of that; 3.7 quarters is still a lot. So far it has not hurt conversion: Q2 2026 operating cash flow of $1.12 billion against $1.10 billion of net income, and $2.55 billion against $2.13 billion for the first half. Collections are not the problem, since annual receivable turns improved from 6.2 to 6.9 between FY2022 and FY2024.
Three items need checking. FY2024's negative $0.49 billion of operating cash flow sits oddly against a loss produced mainly by a non-cash charge; the visible inventory and receivables build is far too small to explain it, and that year's cash flow statement would show whether a tax payment, settlement or milestone drove the gap. Second, non-GAAP results add back about $500 million of Crinetics compensation and transaction expense, some of which is cash compensation; add-backs that recur every year stop being a clean measure of the business. Third, the $4.5 billion term loan is not in the June 30 balance sheet, so liabilities of $7.17 billion and a 26% liabilities-to-assets ratio understate current debt. Interest expense, effectively nil at $0.01 billion in FY2025, now recurs, and the povetacicept PDUFA date of November 30 is the nearest evidence that the acquired pipeline earns a return.
Questions worth following
- Can Vertex hold roughly 33% net margins while funding five franchises, or does launch spending reset the earnings base?
FY2026 GAAP expense guidance of $6.3bn to $6.45bn implies low-to-mid-teens cost growth against high-single-digit revenue growth, while non-CF revenue is guided at only $500m or more. Margin durability depends on whether acute-pain and renal spending buys revenue large enough to cover it.
- Can Vertex carry its new term loan while still funding buybacks?
The company borrowed $4.5 billion while spending about $9.0 billion of net cash on Crinetics and repurchases, shifting a net-cash balance sheet to a levered one. Whether operating cash covers both debt service and distributions, or a further draw is needed, changes the financial risk in the valuation.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc
Business, moat and key questions
Open company page